Upload
amaris
View
27
Download
2
Embed Size (px)
DESCRIPTION
Is treatment-as-prevention the new “game-changer”? Economic evaluation of HIV combination prevention. Till Bärnighausen 1,2 , David E. Bloom 1 , Salal Humair 1,3 1 Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA - PowerPoint PPT Presentation
Citation preview
Is treatment-as-prevention the new “game-changer”? Economic evaluation of HIV combination prevention
Till Bärnighausen1,2, David E. Bloom1, Salal Humair1,3
1Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA2Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa3School of Science and Engineering, Lahore University of Management Sciences (LUMS), Lahore, Pakistan
IAEN Pre-conference meeting, 21 July 2012
Background (1)• On the eve of the June 2011 UN General Assembly High
Level Meeting on AIDS, HIV/AIDS researchers, activists and the press described the results of the HPTN 052 randomized controlled trial (Cohen et al. 2011) as a “game-changer” in the fight against AIDS−Lancet Editorial 2011
−Dickinson 2011
−Clark 2011
−BBC 2011
−Economist 2011
Background (2)• Unclear how TasP could be funded, given flat-lining or
declining financial support for global HIV programs (UNAIDS 2011)
• Unclear when TasP should ideally be implemented. Policymakers could choose not to start implementing TasP until other HIV interventions have reached certain scale levels
• We investigate the cost-effectiveness of different combinations of TasP with two other interventions of proven biological efficacy−Medical male circumcision (MMC) (Auvert et al. 2005; Bailey et al.
2007; Gray et al. 2007)
−Antiretroviral treatment under current eligibility criteria (ART)
ART under current eligibility criteria
0.00
0.20
0.40
0.60
0.80
1.00
1.20
<10% 10-20% 20-30% 30-40% >40%
Adju
sted
haz
ard
ratio
Proportion of all HIV-infected people receiving ART
p=0.002
p<0.001p=0.016
p=0.590
Tanser, Bärnighausen, Grapsa, Newell CROI 2012
Intervention characteristics
MMC ART/TasPDelivery Once-off Life-long
Population in need Larger (e.g. 14 million men for SA)
Smaller (e.g. 2.4 million for TasP for SA)
HIV prevention Acquisition (reduced by 60% per unprotected sex act)
Transmission (reduced by 96% per unprotected sex act)
First-order effect Immediately in men Immediately in women and men
Mortality reduction With delay Immediately
Modeling approach: HIV combination prevention
• Most current models of the HIV epidemic have the limitation that they need to be calibrated to past trends− Limitation that calibration parameter is estimated based on historical
observations and is not guaranteed to remain stable in the future under historically untried interventions (TasP)
− Since calibration parameter is usually a black box and numerically rather than analytically derived from underlying biological and behavioral variables, it is difficult to disaggregate the effects of interventions that operate through different biological or behavioral pathways
• We thus built an analytical model, derived from underlying biological and behavioral mechanisms
Model dynamics
Sexual activityNew HIV infections
Male
HIV+ inflow
Receiving ARTmortality
Not receivingART mortality
Needing ART
HIV stage-specific mortality
Female
Generalmortality
HIV- inflow
Scenarios• A range of different scenarios combining MMC, ART, and TasP
with the following coverage levels (the lowest levels are the current coverage estimates for South Africa)− MMC: 45%, 60%, and 80%
− ART: 50%, 60%, and 80%
− TasP: 0%, 20%, 40%, 60%, and 80%
• All combinations of coverage levels• Coupling of ART and TasP, reflects our belief that that in a real-
life scale-up of TasP, ART coverage of those currently eligible to receive treatment will increase as well
Country application: South Africa• Largest number of HIV-infected individuals in the world
(UNAIDS 2011)• Worldwide largest number of people currently on ART and
needing ART under current guidelines (WHO/UNAIDS/UNICEF 2010)
• High HIV incidence• Political commitment to scaling up MMC but currently
relatively slow rates of increase• Good-quality empirical data
Data• Whenever possible South African national data for base case;
otherwise international sources− Total number HIV-infected and -uninfected: Shisana et al. 2009; StatsSA 2009
− Disease stage distribution and ART coverage: Adam and Johnson 2009
− Time from HIV seroconversion to disease stage: Todd et al. 2007; eART-linc 2008; WHO 2009; Minga et al. 2009
− Annual probability of death by HIV status, disease stage and ART status: Badri et al. 2006; Braitstein et al. 2006; WHO 2009; StatsSA 2009
− Transmission probability in different disease stages: Boiley et al. 2009
− Number of sex partners: Shisana et al. 2009
− Number of sex acts: Global sex survey 2005
− MMC effect: Auvert et al. 2005; Bailey et al. 2007; Gray et al. 2007
− TasP effect: Cohen et al. 2011
− ART and MMC costs: Schwartländer et al. 2011
Results: incidence, mortality and costs
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
0
5,000,000,000
10,000,000,000
15,000,000,000
20,000,000,000
25,000,000,000
Scenarios
HIV
inci
denc
e
Cum
ulat
ive
cost
s ($
bill
ions
)
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
0
5,000,000,000
10,000,000,000
15,000,000,000
20,000,000,000
25,000,000,000
Scenarios
Mor
talit
y ra
te in
HIV
-infe
cted
pe
ople
Cum
ulat
ive
Cos
ts ($
bill
ions
)
Results: HIV incidence for all scenarios
2010 2015 2020 2025 2030 2035 20400.0%
0.2%
0.4%
0.6%
0.8%
1.0%
1.2%
A50%:T0%:C45%A80%:T80%:C80%A70%:T0%:C60%
Year
HIV
Inci
denc
e (p
er y
ear)
A = antiretroviral treatment (ART) under current guidelines, T = treatment-as-prevention (TasP), C = medical male circumcision (MMC)
Results: mortality in all scenarios
2010 2015 2020 2025 2030 2035 20403%
4%
5%
6%
7%
8%
9%
10%
A50%:T0%:C80%A80%:T80%:C45%A70%:T0%:C60%
Year
Annu
al M
orta
lity
in H
IV-In
fect
ed
Peop
le
A = antiretroviral treatment (ART) under current guidelines, T = treatment-as-prevention (TasP), C = medical male circumcision (MMC)
Results: costs in all scenarios
2010 2015 2020 2025 2030 2035 20400
500000000
1000000000
1500000000
2000000000
2500000000
A80%:T80%:C45%A50%:T0%:C80%A70%:T0%:C60%
Year
Cost
per
Yea
r ($
billi
ons)
A = antiretroviral treatment (ART) under current guidelines, T = treatment-as-prevention (TasP), C = medical male circumcision (MMC)
Results: incremental cost-effectiveness ratios
ICER = incremental cost-effectiveness ratio, baseline = ART 50%, MMC 45%, TasP 0%
ICER
US$ per infection averted
US$ per death averted
MMC (80%) vs. baseline
1,096 5,198
ART (80%) vs. baseline + MMC(80%)
7,765 5,741
TasP (80%) vs. MMC (80%) and ART(80%)
14,894 16,180
Further results (1)• Combination of high ART coverage under current
guidelines and high MMC coverage provides approximately the same substantial HIV incidence reduction as TasP
• The combination of high ART and high MMC coverage is considerably less expensive than TasP, requiring approximately US$ 5 billion less over the period 2009-2020
Further results (2)• In costs per infection averted, increased MMC coverage
(with costs of about US$1000 per infection averted) outperforms high ART coverage as well as TasP (both with costs close to US$7000 per infection averted) vs. baseline
• The cost-effectiveness of MMC increases over time; and, unlike ART or TasP, MMC becomes cost-saving after 2040
• MMC becomes cost-saving earlier as TasP coverage increases in the counterfactual scenario
Implication• Our results suggest, that we should first expand MMC coverage and ART coverage under current guidelines to near-universal levels – and only then add TasP to the combination prevention package
Ongoing empirical research• New MMC and ART cost data is becoming available
• Data from the TasP trials will inform the assumptions in economic evaluation−Program costs−Productivity effects−Quality-of-life changes
Acknowledgments• Funding
−World Bank−National Institute of Child Health and Human
Development R01 HD058482-01 and National Institute of Mental Health R01 MH083539-01 (Till Bärnighausen)
Results: costs and mortality
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
0
5,000,000,000
10,000,000,000
15,000,000,000
20,000,000,000
25,000,000,000
Scenarios
Mor
talit
y ra
te in
HIV
-infe
cted
peo
ple
Cum
ulat
ive
Cos
ts ($
bill
ions
)